| Mean ± SD or N (%) |
---|---|
Age (years) | 14 ± 5 |
Height (m) | 1.46 ± 0.18 (n = 65) |
Weight (kg) | 50.1 ± 17.8 |
BSA (m2) | 1.41 ± 0.32 |
Ambulatory | 17(26%) |
Medications at baseline CMR | Â |
 Corticosteroid | 33 (50%) |
 Angiotensin converting enzyme inhibitor | 33 (50%) |
 Beta blocker | 24 (36%) |
 Aldosterone inhibitor | 4 (6%) |
 Angiotensin receptor blocker | 6(9%) |
LVEF (%) | 54.3 ± 9.7 |
LVEDV (mL) LVEDVI (mL/m2) | 93 ± 42 67 ± 20 (n = 65) |
LVESV (mL) LVESVI (mL/m2) | 45 ± 33 32 ± 17 (n = 65) |
LV mass (g) Indexed LV mass (g/m2) | 71 ± 27 49 ± 13 (n = 65) |
Global native T1 (ms) | 1048 ± 44 (n = 54) |
Global εcc (%) | − 14.1 ± 3.5 (n = 64) |
Presence of late gadolinium enhancement (LGE) | 44 (70%) |
Full width half maximum quantification of LGE (%) | 21.3 ± 18.4 (n = 60) |
GSS = 0 | 19 (30%) |
GSS = 1 | 12 (19%) |
GSS = 2 | 12 (19%) |
GSS = 3 | 13 (21%) |
GSS = 4 | 7 (11%) |